RNTX vs. IKT, SLRN, FDMT, LFCR, CCCC, PRQR, LFVN, LRMR, FULC, and OCGN
Should you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Inhibikase Therapeutics (IKT), Acelyrin (SLRN), 4D Molecular Therapeutics (FDMT), Lifecore Biomedical (LFCR), C4 Therapeutics (CCCC), ProQR Therapeutics (PRQR), LifeVantage (LFVN), Larimar Therapeutics (LRMR), Fulcrum Therapeutics (FULC), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry.
Rein Therapeutics vs.
Inhibikase Therapeutics (NYSE:IKT) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Rein Therapeutics' return on equity of -74.08% beat Inhibikase Therapeutics' return on equity.
3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 4.6% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Rein Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.
Inhibikase Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500.
Inhibikase Therapeutics received 9 more outperform votes than Rein Therapeutics when rated by MarketBeat users.
Inhibikase Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 118.86%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Rein Therapeutics.
In the previous week, Inhibikase Therapeutics had 8 more articles in the media than Rein Therapeutics. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 0 mentions for Rein Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.64 beat Rein Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.
Summary
Inhibikase Therapeutics beats Rein Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Rein Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rein Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RNTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RNTX Stock Alerts